Nano-X is set to provide further details and insights during a company-sponsored conference call, which is scheduled for 8 AM Eastern Time on the same day. Investors and interested parties are looking forward to the call for more information on the company's strategy and expectations following the ARC system's expanded indication.
Nano-X is set to provide further details and insights during a company-sponsored conference call, which is scheduled for 8 AM Eastern Time on the same day. Investors and interested parties are looking forward to the call for more information on the company's strategy and expectations following the ARC system's expanded indication.
Nano-X is set to provide further details and insights during a company-sponsored conference call, which is scheduled for 8 AM Eastern Time on the same day. Investors and interested parties are looking forward to the call for more information on the company's strategy and expectations following the ARC system's expanded indication.
Nano-X is set to provide further details and insights during a company-sponsored conference call, which is scheduled for 8 AM Eastern Time on the same day. Investors and interested parties are looking forward to the call for more information on the company's strategy and expectations following the ARC system's expanded indication.
In other recent news, Nano-X Imaging announced its third-quarter operating results, with a revenue increase of approximately 32% year-over-year to $3 million. This revenue was primarily generated by the company's teleradiology services and artificial intelligence solutions, which saw significant growth. Following these results, Cantor Fitzgerald maintained its Overweight rating on Nano-X Imaging but adjusted its price target down to $11 from the previous $14.
The company also reported progress in the deployment of its imaging systems, with approximately 47 systems in various stages of deployment across the United States and a substantial backlog of about 200 systems. These deployments are expected to significantly expand Nano-X's market opportunity.
In addition to these developments, Nano-X is looking forward to achieving important milestones in 2025, including chest and full-body indication approvals, CE Mark, and the ArQX launch. The company's cash position remains robust, with $57.1 million in cash and equivalents. Despite the net loss of $13.6 million, the company's financial health appears to be strong, as indicated by these recent developments.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.